Skip to main content

Table 2 Orally administered anti-diabetic drugs (OAD) and insulin at baseline and the end of the monitoring period

From: Intensification of insulin therapy in patients with type 2 diabetes: a retrospective, non- interventional cohort study of patients treated with insulin glargine or biphasic human insulin in daily clinical practice

 

Control group

Active group

p-value

Start of the monitoring period n (%) or mean value ±  SD

Metformin

71 (44.7)

64 (45.1)

0.942

Sulfonylureas

15 (9.4)

14 (9.9)

0.901

Meglitinides (repaglinide/nateglinide)

0 (0.0)

0 (0.0)

-

Thiazolidinedions

3 (1.9)

10 (7.0)

0.028

Alpha-glucosidase inhibitor

2 (1.3)

1 (0.7)

1.0

Other*

1 (0.6)

0 (0.0)

1.0

Biphasic human insulin (U/day)

47.84 ± 20.05

44.75 ± 19.85

0.18

Biphasic human insulin (U/kg/day)

0.61 ± 0.27

0.56 ± 0.25

0.13

End of the monitoring period n (%)

Metformin

63(39.6)

62 (43.7)

0.478

Sulfonylurea

2 (1.3)

18 (12.7)

<0.001

Meglitinides (repaglinide/nateglinide)

0 (0.0)

6 (4.2)

0.009

Thiazolidinedions

1 (0.6)

7 (4.9)

0.021

Alpha-glucosidase inhibitor

1 (0.6)

1 (0.7)

1.0

Other*

1 (0.6)

2 (1.4)

0.604

Total insulin (glargine or biphasic plus prandial) dose (U/day)

50.89 ± 21.56

42.97 ± 21.53

<0.001

Total insulin (glargine or biphasic plus prandial) dose (U/kg/day)

0.65 ± 0.28

0.53 ± 0.26

<0.001

Change [%, 95% confidence intervals, (CI)] in the OAD and daily insulin dose between baseline and the end of the monitoring period

 

%, 95% CI

%, 95% CI

 

Metformin

-5.0 (-9.5, -0.4)

-1.4 (-6.6, 3.8)

 

p-value (baseline vs end)

0.033

0.593

 

Sulfonylureas

-8.1 (-12.9, 0.4)

2.8 (-3.9, 3.8)

 

p-value (baseline vs end)

0.001

0.393

 

Meglitinides (repaglinide/nateglinide)

0.0

4.2 (0.8, 7.6)

 

p-value (baseline vs end)

-

0.014

 

Thiazolinidiones

-1.3 (-3.0, 0.5)

-2.1 (-5.2, 1.0)

 

p-value (baseline vs end)

0.157

0.180

 

Alpha-glusidase inhibitor

0.0

0.0

 

p-value (baseline vs end)

0.317

-

 

Other*

0.0 (-1.7, 1.7)

1.4 (-0.5, 3.4)

 

p-value (baseline vs end)

1.0

0.157

 

Total insulin (glargine or biphasic plus prandial) dose (U/day)

3.49 (2.16, 4.82)

-1.78 (-5.25, -1.69)

 

p-value (baseline vs end)

<0.001

0.01

 

Total insulin (glargine or biphasic plus prandial) dose (U/kg/day)

0.04 (0.02, 0.06)

-0.02 (-0.07, -0.01)

 

p-value (baseline vs end)

<0.001

0.007

 
  1. *Other includes dipeptidyl-peptidase 4 inhibitors or glucagon-like peptide 1 mimetics.